Shares in Biogen leaped 10% on Friday after the company said that the U.S.
Biogen (BIIB), in collaboration with Eisai, and the Alzheimer’s Clinical Trials Consortium, has initiated a new global Phase 3 clinical study (AHEAD 3-45) …
Biogen Inc. (BIIB) announced that it has finally submitted the Biologics License Application (BLA) seeking approval by the Food and Drug Administration (FDA) …
Biogen (BIIB) has kicked off first quarter biotech earnings with a top- and bottom-line beat. However, the company surprised investors by announcing a …
It’s a short and dramatic plunge for Biogen (BIIB) stock. Today, the biotech giant’s shares lost 29% of their value and reached levels …
Mizuho’s Salim Syed highlights 24% upside potential for BIIB shares, noting most investors were bracing themselves for this Phase II failure.
Eric Schmidt views BIIB shares as undervalued based upon a stable MS franchise and Spinraza’s potential.
Coming off its successful launch of Spinraza, the first drug approved to treat children and adults with spinal muscular atrophy (SMA), Biogen Inc …
Alcobra Ltd Alcobra Ltd (NASDAQ:ADHD) lost half of its value today after announcing that the top-line results from MEASURE, the company’s second Phase …
Chardan analyst Gbola Amusa is placing his confidence behind AveXis Inc (NASDAQ:AVXS) even in light of competitors Biogen Inc (NASDAQ:BIIB) and Ionis Pharmaceuticals …